vs
Apellis Pharmaceuticals, Inc.（APLS）与Turning Point Brands, Inc.（TPB）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Turning Point Brands, Inc.的1.7倍（$199.9M vs $121.0M），Turning Point Brands, Inc.净利率更高（6.8% vs -29.5%，领先36.3%），Turning Point Brands, Inc.同比增速更快（29.2% vs -5.9%），Turning Point Brands, Inc.自由现金流更多（$21.5M vs $-14.3M），过去两年Turning Point Brands, Inc.的营收复合增速更高（20.7% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Turning Point Australia（TPAUS）是一家位于澳大利亚的保守派游说团体，隶属于美国转折点组织但保持独立运营，由乔尔·贾马尔创立并于2023年完成注册。该团体目前正积极行动，试图影响2026年3月举行的南澳大利亚州选举结果。
APLS vs TPB — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $121.0M |
| 净利润 | $-59.0M | $8.2M |
| 毛利率 | — | 55.9% |
| 营业利润率 | -25.6% | 16.5% |
| 净利率 | -29.5% | 6.8% |
| 营收同比 | -5.9% | 29.2% |
| 净利润同比 | -62.2% | 239.8% |
| 每股收益（稀释后） | $-0.40 | $0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $121.0M | ||
| Q3 25 | $458.6M | $119.0M | ||
| Q2 25 | $178.5M | $116.6M | ||
| Q1 25 | $166.8M | $106.4M | ||
| Q4 24 | $212.5M | $93.7M | ||
| Q3 24 | $196.8M | $90.7M | ||
| Q2 24 | $199.7M | $93.2M | ||
| Q1 24 | $172.3M | $83.1M |
| Q4 25 | $-59.0M | $8.2M | ||
| Q3 25 | $215.7M | $21.1M | ||
| Q2 25 | $-42.2M | $14.5M | ||
| Q1 25 | $-92.2M | $14.4M | ||
| Q4 24 | $-36.4M | $2.4M | ||
| Q3 24 | $-57.4M | $12.4M | ||
| Q2 24 | $-37.7M | $13.0M | ||
| Q1 24 | $-66.4M | $12.0M |
| Q4 25 | — | 55.9% | ||
| Q3 25 | — | 59.2% | ||
| Q2 25 | — | 57.1% | ||
| Q1 25 | — | 56.0% | ||
| Q4 24 | — | 56.0% | ||
| Q3 24 | — | 55.6% | ||
| Q2 24 | — | 54.1% | ||
| Q1 24 | — | 58.2% |
| Q4 25 | -25.6% | 16.5% | ||
| Q3 25 | 48.7% | 21.8% | ||
| Q2 25 | -18.6% | 22.6% | ||
| Q1 25 | -50.0% | 21.8% | ||
| Q4 24 | -12.3% | 19.1% | ||
| Q3 24 | -24.0% | 22.9% | ||
| Q2 24 | -14.7% | 24.5% | ||
| Q1 24 | -36.0% | 23.2% |
| Q4 25 | -29.5% | 6.8% | ||
| Q3 25 | 47.0% | 17.7% | ||
| Q2 25 | -23.6% | 12.4% | ||
| Q1 25 | -55.3% | 13.5% | ||
| Q4 24 | -17.1% | 2.6% | ||
| Q3 24 | -29.2% | 13.6% | ||
| Q2 24 | -18.9% | 14.0% | ||
| Q1 24 | -38.5% | 14.5% |
| Q4 25 | $-0.40 | $0.40 | ||
| Q3 25 | $1.67 | $1.13 | ||
| Q2 25 | $-0.33 | $0.79 | ||
| Q1 25 | $-0.74 | $0.79 | ||
| Q4 24 | $-0.30 | $0.15 | ||
| Q3 24 | $-0.46 | $0.68 | ||
| Q2 24 | $-0.30 | $0.68 | ||
| Q1 24 | $-0.54 | $0.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $222.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $372.0M |
| 总资产 | $1.1B | $763.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $222.8M | ||
| Q3 25 | $479.2M | $201.2M | ||
| Q2 25 | $370.0M | $109.9M | ||
| Q1 25 | $358.4M | $99.6M | ||
| Q4 24 | $411.3M | $48.9M | ||
| Q3 24 | $396.9M | $33.6M | ||
| Q2 24 | $360.1M | $142.2M | ||
| Q1 24 | $325.9M | $130.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $372.0M | ||
| Q3 25 | $401.2M | $358.2M | ||
| Q2 25 | $156.3M | $224.8M | ||
| Q1 25 | $164.2M | $203.4M | ||
| Q4 24 | $228.5M | $190.4M | ||
| Q3 24 | $237.1M | $185.7M | ||
| Q2 24 | $264.3M | $172.8M | ||
| Q1 24 | $266.7M | $160.0M |
| Q4 25 | $1.1B | $763.8M | ||
| Q3 25 | $1.1B | $742.8M | ||
| Q2 25 | $821.4M | $595.8M | ||
| Q1 25 | $807.3M | $564.6M | ||
| Q4 24 | $885.1M | $493.4M | ||
| Q3 24 | $901.9M | $488.0M | ||
| Q2 24 | $904.5M | $591.6M | ||
| Q1 24 | $831.9M | $586.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $24.9M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $21.5M |
| 自由现金流率自由现金流/营收 | -7.1% | 17.8% |
| 资本支出强度资本支出/营收 | 0.1% | 2.8% |
| 现金转化率经营现金流/净利润 | — | 3.03× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $43.8M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $24.9M | ||
| Q3 25 | $108.5M | $3.3M | ||
| Q2 25 | $4.4M | $11.8M | ||
| Q1 25 | $-53.4M | $17.4M | ||
| Q4 24 | $19.4M | $17.7M | ||
| Q3 24 | $34.1M | $13.2M | ||
| Q2 24 | $-8.3M | $13.4M | ||
| Q1 24 | $-133.0M | $22.6M |
| Q4 25 | $-14.3M | $21.5M | ||
| Q3 25 | $108.3M | $-721.0K | ||
| Q2 25 | $4.4M | $7.8M | ||
| Q1 25 | $-53.4M | $15.2M | ||
| Q4 24 | $19.3M | $16.6M | ||
| Q3 24 | — | $12.6M | ||
| Q2 24 | $-8.4M | $10.9M | ||
| Q1 24 | $-133.3M | $22.3M |
| Q4 25 | -7.1% | 17.8% | ||
| Q3 25 | 23.6% | -0.6% | ||
| Q2 25 | 2.5% | 6.7% | ||
| Q1 25 | -32.0% | 14.3% | ||
| Q4 24 | 9.1% | 17.8% | ||
| Q3 24 | — | 13.9% | ||
| Q2 24 | -4.2% | 11.7% | ||
| Q1 24 | -77.3% | 26.8% |
| Q4 25 | 0.1% | 2.8% | ||
| Q3 25 | 0.0% | 3.4% | ||
| Q2 25 | 0.0% | 3.4% | ||
| Q1 25 | 0.0% | 2.1% | ||
| Q4 24 | 0.0% | 1.2% | ||
| Q3 24 | 0.0% | 0.7% | ||
| Q2 24 | 0.0% | 2.7% | ||
| Q1 24 | 0.2% | 0.4% |
| Q4 25 | — | 3.03× | ||
| Q3 25 | 0.50× | 0.16× | ||
| Q2 25 | — | 0.82× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | 7.34× | ||
| Q3 24 | — | 1.07× | ||
| Q2 24 | — | 1.03× | ||
| Q1 24 | — | 1.89× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
TPB
| US | $111.5M | 92% |
| Non Us | $9.6M | 8% |
